Predicting Functional Responses of Progenitor Cell Exosome Potential with Computational Modeling

DAVID TRAC, a JESSICA R. HOFFMAN, b SRUTI BHERI, a JOSHUA T. MAXWELL, b MANU O. PLATT, a MICHAEL E. DAVIS a,b,c

Key Words. Stem cells • Computational biology • Heart failure • MicroRNAs • Statistical regression • Least-squares analysis

ABSTRACT

Congenital heart disease can lead to severe right ventricular heart failure (RVHF). We have shown that aggregated c-kit+ progenitor cells (CPCs) can improve RVHF repair, likely due to exosome-mediated effects. Here, we demonstrate that miRNA content from monolayer (2D) and aggregated (3D) CPC exosomes can be related to in vitro angiogenesis and antifibrosis responses using partial least squares regression (PLSR). PLSR reduced the dimensionality of the data set to the top 40 miRNAs with the highest weighted coefficients for the in vitro biological responses. Target pathway analysis of these top 40 miRNAs demonstrated significant fit to cardiac angiogenesis and fibrosis pathways. Although the model was trained on in vitro data, we demonstrate that the model can predict angiogenesis and fibrosis responses to exosome treatment in vivo with a strong correlation with published in vivo responses. These studies demonstrate that PLSR modeling of exosome miRNA content has the potential to inform preclinical trials and predict new promising CPC therapies. Stem Cells Translational Medicine 2019;8:1212–1221

SIGNIFICANCE STATEMENT

With ongoing clinical trials using stem and progenitor cells in children, there is a greater need to better understand the potential mechanisms. Computational modeling has been used to investigate the signals that contribute to repair of the injured right ventricle. This study examines the contents of pediatric progenitor cell exosomes, uses existing computational models to predict functional mechanisms, and then makes a priori predictions on in vitro and in vivo data. This could have far-reaching implications in personalized precision medicine for children with heart failure.

INTRODUCTION

Congenital heart disease (CHD) affects an estimated 40,000 infants each year in the U.S. [1]. Improved surgical outcomes and medical management has led to an aging of the CHD population [2]. Stem cell therapy, including c-kit+ progenitor cells (CPCs), is currently being studied as a potential treatment for right ventricular heart failure (RVHF) occurring in complex forms of CHD, such as hypoplastic left heart syndrome (NCT03406884). But older CPCs, starting as early as 1 year old, have been shown to reduce reparative ability [3, 4]. In a recent publication, we showed that aggregating CPCs into spheres can improve their ability to repair RVHF, likely due to exosome-mediated effects [5].

Exosomes are 20–150 nm vesicles that carry a variety of proteins, lipids, and noncoding RNAs. Altering the parental cells under different treatment conditions can alter exosome cargo, but the effect is not deterministic. We have previously shown that subjecting CPCs to hypoxic treatment alters exosome content, but not all miRNAs enriched in the exosomes were upregulated in the cell [6]. Additionally, while thousands of different miRNAs were identified in these exosomes, miRNAs comprised only ~1% of exosome noncoding RNA sequences. Therefore, it is important to investigate the combinatorial effect of groups of miRNAs and how they change in response to different treatments as it relates to exosome functional responses. We have previously demonstrated that a systems biology approach using statistical tools can model variations in exosome cargo and predict functional outcomes from exosome therapy [4, 6, 7].

In the present study, we use partial least squares regression (PLSR), a data-driven computational modeling technique, to establish a mathematical relationship between miRNA levels of exosomes produced from monolayer (2D) and...
spherically aggregated (3D) CPCs, and biological responses of X
and Y in P and Q types of cells after uptake of these exosomes in
vitro. Then, using an unbiased approach, we reduce that
model to the most important variables (miRNA signals) for the
model’s prediction of biological responses. We demonstrate the
capability of this model to make a priori predictions of in vitro
responses from additional biological cues based on the miRNA
levels, and then demonstrate the model’s ability to predict
in vivo responses of angiogenesis and fibrosis in a rat myocardial
infarction model, with strong correlation to experimentally
observed responses. To the best of our knowledge, this is the
first example of using a miRNA computational model trained
in vitro responses to predict in vivo outcomes. Our results
represent a step toward bridging gaps between in vitro and
animal or human studies.

MATERIALS AND METHODS

Human Sample Acquisition and Isolation of
Human CPCs
This study was approved by the Institutional Review Board at
Children’s Healthcare of Atlanta and Emory University. Human
c-kit+ CPCs used in this study were isolated from right atrial
appendage tissue routinely removed during surgical repair of
congenital heart defects as previously described [4]. Child CPCs
were isolated from three patients aged between 3 and 6 years,
identified as 1048, 1063, and 1092.

CPC Culture and Sphere Formation
Cells were used between passages 5 and 9. As previously
described, CPC spheres were formed by seeding 1,500 cells
per microwell in an AggReWell400 microwell array (Stemcell
Technologies, Vancouver, BC, Canada) and culturing overnight
[5]. CPC spheres have been previously shown to have high cell
viability and promote endothelial-like differentiation [5].

Exosome Generation
Exosomes were generated as previously described [7]. Briefly,
after 3 or 7 days in culture, 2D and c-kit+ progenitor cells cultured
as spheres (3D CPCs) were quiesced and cultured in fetal bovine
serum (FBS)-free media for 12 hours to generated conditioned
media. Exosomes were generated from conditioned media by
sequential ultracentrifugation (Optima XPN-100, SW32Ti rotor,
Beckman Coulter, Indianapolis, IN) at 10,000 × g for 35 minutes to
remove cell debris and then at 120,000 × g for 70 minutes to con-
centrate exosomes. Successful exosome isolation was confirmed
by transmission electron microscopy. Protein content of the
exosome suspension was quantified by transmission electron microscopy. Protein content of the
exosome suspension was quantified by TransmissionElectron Microscopy. Exosome Generation

Real-Time PCR
Real-time PCR was then performed on the StepOne System
(Applied Biosystems, Foster City, CA) based on SYBR Green
fluorescence detection of PCR products. miRNA specific primer
sequences were designed by Quantabio (Beverly, MA).

miRNA Sequencing and Analysis
miRNA was purified from exosomes using Qiagen miRNeasy kit
(Redwood City, CA). Purified miRNA was analyzed (2100 Bio-
analyzer, Agilent Genomics, Santa Clara, CA) for miRNA size, qual-
ity, and quantity. miRNA library was prepared using CleanTag
Small RNA Library Prep Kit (TriLink Biotechnologies, San Diego, CA).
Next generation sequencing was performed using a HiSeq3000
(Illumina, San Diego, CA) by the Emory Yerkes National Primate
Research Center. miRNA sequence alignment and differential
expression was processed using the Small RNA App in BaseSpace
(Illumina, San Diego, CA).

Following 12-hour quiescence in EGM-2 media supplemented
with 0.2% FBS only, CECs were treated with 20 μg/ml exosomes for 12 hours. Cells were then lifted and then plated
on 75 μl Matrigel (6 μg/ml protein, Corning, Corning, NY) thick
gels in 96-well plates with 15,000 cells per well to allow for
tube formation. Cells were stained with 2 μg/ml Calcein AM
and imaged 4 hours after plating by using a fluorescent micro-
scope (Olympus IX71, Olympus Corporation, Shinjuku, Tokyo,
Japan). Tube length was quantified using ImageJ (Fiji, National
Institutes of Health, Bethesda, MD). To account for variability
in tube formation between experiments, each experiment was
normalized to an untreated negative control that received
EGM-2 media supplemented with 0.2% FBS only. Positive con-
trols were cultured in EGM-2 media containing all supple-
ments listed above.

Fibroblast TGF-β Stimulation Assay
Rat cardiac fibroblasts (RCFs) were cultured in Dulbecco’s modi-
ﬁed Eagle’s medium supplemented with 10% FBS, 1% l-glu-
tamine, 1% penicillin, and 1% streptomycin. RCFs were quiesced
for 12 hours in media with reduced FBS (1%), treated with
20 μg/ml exosomes for 12 hours, and then stimulated with
transforming growth factor beta (TGF-β), final concentration of
10 ng/ml) for another 12 hours. Cells were then collected and
RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad,
CA) per manufacturer’s protocol. Real-time PCR (RT-PCR) RT-
PCR was performed to evaluate transcript expression of connec-
tive tissue growth factor (CTGF), collagen type 1 pro-α1 chain
(COL1A1), collagen type 1 pro-α2 chain (COL1A2), collagen type
3 pro-α1 chain (COL3A1), and vimentin (VIM). Data were com-
pared with positive control (TGF-β stimulation without exosome
treatment). Negative control represents RCFs that were not stim-
ulated with TGF-β and not treated with exosomes.

Tube Formation Assay
Rat cardiac endothelial cells (CECs) were cultured in endothe-

iastria}
Principal Component and PLSR Analysis

miRNA sequencing analysis determined mature miRNA hits. Hits values were first transformed to their natural logs. To generate the PLSR model, SIMCA-P software (Umetrics, Sartorius Stedim Biotech, Umeå, Sweden) was used as previously described to solve the PLSR problem with the nonlinear iterative partial least squares algorithm [8, 9]. miRNA expression determined in additional exosome samples by real-time PCR was normalized to real-time PCR miRNA expression data from 3D 7-day exosomes using the fold change (ΔΔCt method). For each matched CPC donor population, fold change values were then used to generate theoretical hits per miRNA by comparing with miRNA sequencing data from 3D 7-day exosomes. The normoxia/hypoxia data set, previously generated by Affymetrix microarray analysis, was transformed and incorporated into the PLSR model trained on in vitro data to form in vivo predictions of angiogenesis and fibrosis. From the raw expression data, the minimum value for each miRNA was subtracted across the exosome samples. A scaling factor was then created for each miRNA by considering the average miRNA expression from the 2D/3D versus the normoxia/hypoxia exosomes. In vivo angiogenesis and fibrosis were measured in this previously published study as capillaries per mm² and percent left ventricle fibrotic area [6]. Angiogenesis measurements were normalized to the lowest value before inserting into the PLSR model; higher values represent more angiogenesis and lower values represent less angiogenesis. Fibrosis measurements were normalized to the average of all values before inserting into the PLSR model; higher values represent more fibrosis and lower values represent less fibrosis.

miRtarBase was used to identify miRNAs with known targets (validated by at least three assays; http://mirtarbase.mbc.nctu.edu.tw). miRNA target pathways were analyzed by Ingenuity Pathway Analysis (Qiagen, Redwood City, CA). Top ranking networks were selected with scores defined as the -log (Fischer’s Exact test result).

Statistical Analysis

The OriginPro 2016 software (OriginLab Corporation, Northampton, MA) or GraphPad (Graphpad Software, San Diego, CA) was used to perform statistical tests as described in the figure legends. All data sets were significantly drawn from a normally distributed population at the 0.05 level using Kolmogorov–Smirnov’s test for normality.

Chemicals and Reagents

Unless otherwise stated, all reagents were purchased from Sigma–Aldrich (St. Louis, MO).

RESULTS

Effect of Exosomes on Tube Formation and Fibrotic Gene Expression

Different child CPC donor populations (1048, 1063, and 1092) were cultured as monolayers (2D) or spherical aggregates (3D) produced using a microwell array as previously described [5]. Exosomes were generated from 2D and 3D CPCs at days 3 and 7 in culture (Supporting Information Fig. S1). The angiogenic effects of exosomes on CECs were investigated using a tube formation assay. 3D 7-day CPC exosomes significantly improved total tube length compared with 2D CPC exosomes and 3D 3-day CPC exosomes (Fig. 1A, 1B). Average tube length was not significantly improved. The antifibrotic effects of exosomes on rat cardiac fibroblasts (RCFs) was investigated using a fibroblast TGF-β stimulation assay. Treatment of TGF-β stimulated fibroblasts with exosomes from 3D 3-day CPCs significantly reduced COL3A1 and VIM transcript expression compared with TGF-β only control (+; Fig. 1C). Exosomes from 3D 7-day CPCs significantly reduced CTGF, COL1A1, COL1A2, and VIM transcript expression compared with TGF-β only control (+), as previously published [5]. RCFs had greater uptake of exosomes than CECs, with no significant differences in uptake between exosome treatment groups (Supporting Information Fig. S2).

PLSR Modeling of CPC Exosome miRNA Signals and In Vitro Responses to Exosome Treatment

PLSR was used to establish a relationship between the cues (2D or 3D and 3-day or 7-day) and the responses of in vitro angiogenesis and antifibrosis responses, using the signals (miRNA levels) to derive mathematical relationship in an unbiased approach (cue-signal-response paradigm). Of the 2,588 mature miRNAs sequenced, 218 miRNAs had nonzero hits and 107 miRNAs had nonzero values for at least three samples. PLSR identified the most important signals for the biological responses by calculating variable importance for projection (VIP) scores using a weighted sum of squares for a 2-component model. The signals projecting strongly (either positively or negatively) with a response were highly ranked. The model was reduced to the top 40 highest ranking miRNAs (Supporting Information Fig. S3). The top 40 VIP miRNAs were then fit to a 3-principal component model. In a 3-principal component model, these 40 miRNAs captured the variance in the signals (X-variable matrix) and responses (Y-variable matrix) with high coefficients of determination (R²X = 0.856, R²Y = 0.514). The cumulative variance captured by each component is given in Supporting Information Figure S4A. The variance captured by each component for individual in vitro responses is given in Supporting Information Figure S4B. As expected, principal components 1 and 2 captured the majority of in vitro response variance. However, the inclusion of principal component 3 greatly improved the predictability of COL3A1, VIM, and average tube length (Supporting Information Fig. S4B). We generated separate models with varying numbers of top scoring VIP miRNA signals included and found that a model with the top 40 VIPS maximized R²X and R²Y values while minimizing data input required. For example, a three-principal component model with more VIPS (top 60) had only marginally higher R²X (0.858) and a model with less VIPs (top 20) had reduced overall R²Y (0.412).

Scores plot of the 3-principal component fit of the data shows separation of 2D and 3D CPC exosomes across principal component 1 (Fig. 2A). 3D 7-day exosomes were further separated by principal component 2 from 3D 3-day exosomes. These data suggest that component 1 likely represents dimension of culture condition and component 2 likely represents dimension of culture time. The poor separation of 2D 3-day and 7-day exosomes suggests no significant difference in miRNA expression between these conditions. Plotting the miRNA signals and the in vitro responses in the same component space in a loadings plot illustrates the influence that each miRNA signal has on a response in relation to all the other signals. The loadings plot shows separation of angiogenesis measures (total tube formation length and average tube formation length) and fibrosis
measures (CTGF, COL1A1, COL1A2, COL3A1, VIM) across principal components 1 and 2 (Fig. 2B). Angiogenesis responses had negative loadings values in components 1 and 2, corresponding with 3D 7-day cues in the scores plot. This affirms our observed data showing improved tube formation with 3D 7-day exosome treatment. CTGF, COL1A1, and COL1A2 had positive loadings values in principal components 1 and 2. This suggests that these responses are negatively correlated with 3D 7-day exosome cues, as affirmed by our previously published data showing reduced expression of CTGF, COL1A1, and COL1A2 with 3D 7-day exosome treatment in vitro [5]. Similarly, VIM and COL3A1 were negatively correlated with 3D 3-day exosome cues. The top 40 VIP miRNAs predicted in vitro responses with high coefficients of determination, with the exceptions of COL1A1 and COL1A2 (Fig. 2C). The predictive ability of the model was calculated based on cross-validation boot-strapping method, performed by omitting an observation from training the model and then using that model to predict responses without the withheld observation. This procedure was repeated until every observation had been excluded exactly once. The cumulative value for the predictive ability of the model was evaluated after addition of each component and is given as $Q^2$ (cum) in Supporting Information Figure S4A. Scores and loadings plots showing principal components 1 versus 3 and components 2 versus 3 are given in Supporting Information Figure S5.

**Validation of miRNA Expression and Covariance**

To validate the covariance of miRNAs with responses, the expression of miRNAs miR-28-3p, miR-320a, miR-423-5p, and miR-323a-3p was quantified in CECs and RCFs treated with 2D and 3D 7-day exosomes (Fig. 3). These miRNAs were chosen because they had the highest weighted coefficients for angiogenesis and fibrosis responses in principal component 3. Exosome treatment increased expression of miRNAs compared with untreated cells, suggesting that exosomes successfully targeted and delivered miRNA cargo to CECs and RCFs. These data agree with previously published data demonstrating CPC exosome uptake by endothelial cells and fibroblasts [4, 6]. Because angiogenesis and fibrosis responses were segregated across principal components in our model, we expect that miRNAs that covary with angiogenesis measures would lead to opposite changes in exosome-treated fibroblasts versus exosome-treated endothelial cells. Indeed, we found that 3D CPC exosome treatment increased the expression of miRNAs that covaried with tube formation (miR-28-3p, miR-320a, and miR-423-5p) in CECs but not in RCFs. miR-323a-3p, which was quantified in vitro responses with high coefficients of determination, with the exceptions of COL1A1 and COL1A2 (Fig. 2C). The predictive ability of the model was calculated based on cross-validation boot-strapping method, performed by omitting an observation from training the model and then using that model to predict responses without the withheld observation. This procedure was repeated until every observation had been excluded exactly once. The cumulative value for the predictive ability of the model was evaluated after addition of each component and is given as $Q^2$ (cum) in Supporting Information Figure S4A. Scores and loadings plots showing principal components 1 versus 3 and components 2 versus 3 are given in Supporting Information Figure S5.

**Validation of miRNA Expression and Covariance**

To validate the covariance of miRNAs with responses, the expression of miRNAs miR-28-3p, miR-320a, miR-423-5p, and miR-323a-3p was quantified in CECs and RCFs treated with 2D and 3D 7-day exosomes (Fig. 3). These miRNAs were chosen because they had the highest weighted coefficients for angiogenesis and fibrosis responses in principal component 3. Exosome treatment increased expression of miRNAs compared with untreated cells, suggesting that exosomes successfully targeted and delivered miRNA cargo to CECs and RCFs. These data agree with previously published data demonstrating CPC exosome uptake by endothelial cells and fibroblasts [4, 6]. Because angiogenesis and fibrosis responses were segregated across principal components in our model, we expect that miRNAs that covary with angiogenesis measures would lead to opposite changes in exosome-treated fibroblasts versus exosome-treated endothelial cells. Indeed, we found that 3D CPC exosome treatment increased the expression of miRNAs that covaried with tube formation (miR-28-3p, miR-320a, and miR-423-5p) in CECs but not in RCFs. miR-323a-3p, which
Figure 2. Partial least squares regression modeling of c-kit+ progenitor cell (CPC) exosome miRNA signals and in vitro responses to exosome treatment. A three-component model was trained using the top 40 miRNA variables of importance for the model projection (variable importance for projections [VIPs]). (A): Scores plot of component 1 versus 2 from partial least squares regression (PLSR) analysis trained with 2D or 3D, 3-day or 7-day treatment with top 40 VIPs. 1048, 1063, and 1092 represent different child CPC donors. (B): Loadings plots of components 1 versus 2 show VIP miRNA signals covarying with in vitro responses of angiogenesis (total tube formation length, average tube formation length) and fibrosis (mRNA expression of connective tissue growth factor, COL1A1, COL1A2, COL3A1, and VIMENTIN). miRNAs with the highest weighted coefficients for angiogenesis (light blue) and fibrosis (light red) in component 3 are highlighted. (C): PLSR model predictions of in vitro responses correlated with observed measurements.

A miRNA expression in exosome-treated cardiac endothelial cells

miR-28-3p, miR-320a, and miR-423-5p covaried with tube formation measures (bottom left quadrant of loadings plot in Fig. 2B) and miR-323a-3p covaried with fibrotic gene expression (top right quadrant). The expression of these miRNAs was quantified using real-time PCR in 2D and 3D exosome-treated cardiac endothelial cells (A) and cardiac fibroblasts (B). Data represent cycle threshold (Ct) ± SD. Lower Ct values represent higher expression. Dotted line represents untreated control. Significance was tested using Student’s paired t test. 1048, 1063, and 1092 represent different child CPC donors.

© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by STEM CELLS TRANSLATIONAL MEDICINE Wiley Periodicals, Inc. on behalf of AlphaMed Press
covaried with fibrotic gene expression responses, was increased in RCFs with 3D exosome treatment, but not in CECs. These data demonstrate that cumulative, small nonsignificant changes in groups of miRNAs can produce significant biological responses. miRNAs yield themselves to amplified responses because they can target several pathways and can be agonists or antagonists to multiple genes. Transfection of miRNAs with high-positive weighted component 3 coefficients for tube formation (miR-320a and miR-423-5p) into CECs increased tube formation compared with nontransfected CECs (Supporting Information Fig. S6).

miRNA Target Analysis

The top 40 VIP miRNAs were queried for experimentally validated targets using miRTarBase. Thirty-seven of the 40 miRNAs had confirmed targets by at least three assays. Pathway analysis of these targets showed significant fit to tissue development networks and important cardiovascular signaling pathways (Fig. 4). Angiogenesis is a complex process involving multiple signaling pathways. Several pathways that have been shown to play key roles in angiogenesis were highlighted by ingenuity pathway analysis including: PTEN signaling [10], JAK/stat signaling [11], P2Y purergic receptor signaling [12], angiopoietin signaling, HIF1α signaling [13, 14], and nitric oxide signaling [15]. Pathway analysis also identified apelin signaling, which has been shown to regulate endothelial cell proliferation and angiogenesis in the heart and prevent cardiac fibroblast activation and collagen production [16, 17]. Additionally, 15 of the 218 miRNAs with nonzero hits were verified to target one or more of our fibrosis measures: CTGF, COL1A1, COL1A2, COL3A1, and VIM (Supporting Information Table S1). Of these 15, three miRNAs (miR-378a-3p, miR-134-5p, and miR-320a) were included in our top 40 VIPs and all target VIM. Although the effect of exosomes on cardiac hypertrophy was not measured in vitro, pathway analysis highlighted the calcineurin-NFAT signaling pathway, which has been shown to regulate the cardiac hypertrophic response [18]. This suggests that 3D CPC exosomes could have played a key role in attenuating cardiac hypertrophy in our previously published study [5].

A Priori Prediction of the Effect of Notch Inhibition on Exosome Function in 3D CPCs

Notch signaling plays an important role in regulating CPC differentiation [19–22]. Moreover, we have recently shown that 3D CPCs improve RV vessel density in a RVHF rat model in a Notch-dependent manner [5]. However, the effect of Notch1 inhibition
1218 Predicting CPC Exosome Function with PLSR

Hypoxic and normoxic treatment using Affymetrix GeneChip previously quantified miRNA levels were normalized as detailed in the methods. MiRNA levels were quantified in 3D + Ni 7-day exosome samples using real-time PCR and plugged into partial least squares regression model. (A): Model predictions of in vitro responses to exosomes from 3D 7-day c-kit+ progenitor cells (CPCs) transduced with Notch1-shRNA (3D + Ni) compared with 3D 7-day CPCs. (B): Representative image of blood vessel-like structures formed by rat cardiac endothelial cells (CECs) stained with Calcein on Matrigel. CECs were treated with 3D + Ni exosomes. Scale bar = 100 μm. Total tube length formed by CECs were quantified in ImageJ and normalized to negative control. Data represented as individual samples and average ± SD. Dotted lines represent positive (+) control value and negative (−) control values. *, p ≤ 0.05 with Student’s t test. (C): Predicted total tube length based on VIP miRNA expression in 3D + Ni samples correlated with new observations. 1048, 1063, and 1092 represent different child CPC donors.

Using In Vitro Trained Computational Model to Predict In Vivo Functional Outcomes

We then tested the capability of the PLSR model, trained with in vitro functional data, to predict in vivo angiogenesis and fibrosis results from a previously published study [5]. We have previously shown that exosomes from CPCs isolated from neonate patients (0–1 month old) have greater ability to repair the heart after myocardial ischemia and reperfusion injury than exosomes from CPCs isolated from child patients (1–5 years old), and that hypoxic treatment enhances the ability of both neonate and child CPC exosomes to repair the heart [6]. In these prior studies, angiogenesis was measured as the number of vessels in the peri-infarct zone 28 days postexosome delivery. Reductions in cardiac fibrosis 28 days postexosome delivery were observed using picrosirius red staining, which stains for collagen I and collagen III fibers, and quantified as percent fibrotic tissue area. In vivo measurements were normalized as detailed in the methods. MiRNA levels were previously quantified in neonate and child CPC exosomes after hypoxic and normoxic treatment using Affymetrix GeneChip analysis. These miRNA expression values were transformed to match our current model’s VIP miRNA values analyzed using RNAseq, as detailed in the methods, and inserted into the model. Thirty out of 40 VIP signals were analyzed in the prior publication. Average tube formation length and COL3A1 expression responses served as the analogs for in vivo angiogenesis and fibrosis data, respectively, in the PLS model described in Figure 2. Without additional model training, the in vitro PLS model predictions correlated with observed in vivo responses.

Figure 5. PLSR model predicts in vitro tube formation in response to 3D + Ni exosome treatment. Top 40 variable importance for projection (VIP) miRNAs were quantified in 3D + Ni 7-day exosome samples using real-time PCR and plugged into partial least squares regression model. Predicted total tube length with 3D + Ni exosome treatment as lower than predicted 3D exosome treatment (Fig. 5A). To verify model predictions, tube formation assay was then performed using 3D + Ni exosomes (Fig. 5B). Total tube formation length with CECs was significantly lower with 3D + Ni 7-day exosome treatment compared with 3D 7-day exosome treatment. Predicted total tube length values correlated strongly with observed responses (Fig. 5C). Correspondingly, one of the miRNAs with high positive weighted component 3 coefficients for tube formation (miR-423-5p) was decreased in CECs treated with 3D + Ni 7-day exosomes compared with 3D exosomes (Supporting Information Fig. S7).

Figure 6. In vitro model successfully predicts in vivo angiogenesis and fibrosis in response to c-kit+ progenitor cell (CPC) exosomal therapy. Exosomes were isolated from CPCs donated by neonate (0–1 month old) and child (1–5 years old) patients cultured under normoxic and hypoxic conditions. Exosome miRNA content, determined by Affymetrix GeneChip analysis, and in vivo angiogenesis and fibrosis responses to CPC exosome therapy in a myocardial ischemia/reperfusion injury rat model were previously published in reference 6. In vitro average tube formation length and COL3A1 expression responses served as the analogs for in vivo angiogenesis and fibrosis data, respectively, in the PLS model described in Figure 2. Without additional model training, the in vitro PLS model predictions correlated with observed in vivo responses.


**DISCUSSION**

Exosomes are generated by nearly all cell types and have emerged as an attractive therapy to improve cardiac repair. Herein, we use a systems biology approach to create a predictive model using exosome miRNA signals. Our results demonstrate that, by sorting for top VIP miRNA signals, a reduced model can be generated that strongly predicts angiogenesis and fibrosis changes in response to exosome treatment both in vitro and in vivo. Many studies have shown that stem cell exosomes mimic the regenerative properties of their parental stem cells and that blockade of exosome secretion reduces the effectiveness of stem cell therapy [23–26]. Exosome therapies have low immunogenicity and have quickly progressed to clinical trials for intractable cutaneous ulcers (NCT02565264) and type-I diabetes mellitus (NCT02138331) [27]. Although these studies demonstrate promise for exosome therapy in patients with cardiovascular diseases, more comprehensive characterization of exosome cargo and better understanding of the mechanisms governing the loading of exosome cargo from the parent cell are required.

In recent years, data gathering methods have shifted focus to high-throughput techniques capable of measuring thousands of variables. In our study, we used miRNA sequencing and evaluated the expression of 2,488 mature miRNAs under 12 different conditions. The large quantity of data variables generated by high-throughput techniques, such as RNA sequencing, places emphasis on data analysis tools that can reduce the dimensionality of the data to form meaningful conclusions. PLSR is helpful in this regard by identifying linear relationships within the variables and matching them to outputs, which the user can associate with biological information. An important advantage of PLSR is that the fully trained model can be used to calculate quantitative predictions of responses of signal data sets from new cues that were not included in the training set. Because PLSR considers contributing vectors and not each individual data point for every cue, PLSR has the added benefit of accommodating unknown coefficients and incomplete data sets, which may have been key in using in vitro data collections to predict in vivo outcomes during this study.

In the present study, we trained a PLSR model using miRNA expression data from CPC exosomes from children undergoing CHD repair. Although patient-to-patient variability in responses were captured by exosomal miRNA content in our PLSR model, exosomes produced by 2D 3-day CPCs from donor 1048 generated higher COL1A1 and lower COL1A2 fold change expression in treated RCFs than expected (COL1A1: predicted: 1.97, observed: 5.09; COL1A2: predicted: 0.92, observed: 0.26; Fig. 2C). Considering exosomes contain many other factors outside of mature miRNAs, these data suggest that exosomes from CPCs generated from patient 1048 may contain non-miRNA factors that are responsible for the observed functional response. Studying other noncoding RNAs or proteomics analyses in this CPC population may reveal novel targets to modulate fibroblast activity. Our data additionally showed differences in miRNA expression between endothelial cells and fibroblasts treated with 3D 7-day exosomes, suggesting the presence of two subpopulations of exosomes (Fig. 3). Quantifying exosome size also demonstrated two subpopulations of 3D 7-day exosomes separated by size (Supporting Information Fig. S1). In light of studies demonstrating the cellular release of multiple subpopulations of exosomes with distinct biological properties upon activation or stimulation, 3D aggregation may promote the release of exosomes designed specifically to target and alter the function of endothelial cells or fibroblasts [28, 29]. Additionally, there was clearly a time-dependent expression of miRNAs within the exosomes as exosomes derived from earlier time points only induced changes in fibrotic markers, whereas exosomes derived from later time points induced changes in both fibrotic markers and angiogenesis. As several groups are now creating designer exosomes, these data could facilitate the rational design of exosome cargo and vesicle membrane to maximize exosome function and control exosome uptake [30].

Out of the 40 miRNAs selected for the model described in Figure 2, 30 miRNAs were matched with data from the study by Agarwal et al. [6]. Inputting matching data for just 30 out of the top 40 miRNAs enabled the model to predict in vivo responses with strong correlation (Fig. 6). Comparing the top 40 VIP signals identified in this model with the top 30 VIPs published by Agarwal et al. reveals four miRNAs in common: miR-125b-1-3p, miR-148a-3p, miR-335-3p, and miR-486-5p. The presence of these miRNAs in both models suggests that they may play well-conserved roles in angiogenesis and anti-fibrosis across CPC donor ages (neonate and child) and CPC treatment conditions (aggregation and hypoxia). Using average tube length and COL3A1 as analogs generated the highest predictability of in vivo responses to child and neonate, normoxia, and hypoxia exosomes. Interestingly, the variance of average tube length values and COL3A1 expression captured within the model improved drastically with the inclusion of component 3, which captures an additional vector of covariance among the signals, distinct from principle components 1 and 2 (Supporting Information Fig. S4B). Together, these findings suggest that component 3 may represent the dimension of CPC donor patient age. Although we have previously published predictive PLSR models trained with exosome miRNA signals, this is the first example, to the best of our knowledge, of using a miRNA model trained on in vitro responses (cells) to predict in vivo outcomes (rodent models).

Although the model in our current study utilizes only a handful of cues (2D vs. 3D, age, oxygen tension, Notch activity), our results demonstrate that our data-driven, statistical model may help to predict novel combinations of CPC therapies that maximize exosome therapeutic functionality and provide a computational platform to test them prior to costly experiments. Studies using CPCs and CPC-related cardiac stem cells have used multiple different strategies to improve CPC function, including environmental and chemical cues, hydrogels, biomimetic scaffolds, electrical stimulation, gene-editing tools, and lentiviral transduction [31-35]. As more exosome miRNA data sets from these, and other, CPC and CPC-related stem cell modifications become available, our PLSR model can be expanded to generate more robust predictions for a larger breadth of responses and cellular modifications. It should also be noted that our sample size was low for generating a model. This was due to patient availability and was consistent with our published studies using three patients as a representative...
cohort. Despite this low number, the patients were similar in age and diagnosis (septal defects) and we were still able to capture the variability. As more samples are obtained, we will be able to add to the model and refine our conclusions.

PLSR analysis allows the user to evaluate different types of signals and their contributions to given responses, not just limited to miRNA levels. For example, large amounts of clinical data are collected on patients currently enrolled in clinical trials for cardiac stem cell therapies, such as blood pressure, oxygen saturation, body weight, and so forth. Each of these parameters alone may not be predictive of patient clinical improvement. However, we have shown that small changes in groups of miRNAs can be correlated to significant biological responses in vitro (Figs. 1 and 3). Similarly, small changes in groups of clinical parameters may be correlated to significant clinical responses in patients. Incorporation of patient characteristics and clinical data into the PLSR model created a clinically useful tool to predict which patients may respond well to cell therapy and which patients may respond poorly to cell therapy and may benefit from greater intervention. As exosome therapies transition into clinical trials, identifying patient characteristics associated with highly responsive “responder” exosomes can facilitate the development of more potent therapeutics.

CONCLUSION

The strong prediction of in vivo exosome function from in vitro analyses represents a step toward producing patient-specific exosome therapeutics. These studies can identify optimal donors and stem cell manipulations predicted to improve exosome function before performing in vivo experiments. Combinations of high-performing donor cell exosomes or stem cell manipulations can produce maximally functional exosome therapeutics. Further studies may use exosome miRNA data in combination with patient characteristics to predict clinical outcomes in patients. Although our approach does not identify causative mechanisms, the unbiased and quantitative selection of cues and signals allows for improved understanding of CPC exosome effects and has the potential to be extended to predict exosome function for similar outcomes in other diseases.

REFERENCES

1. Benjamin EM, Virani SS, Callaway CW et al. Heart disease and stroke statistics—2018 update: A report from the American Heart Association. Circulation 2018;137:e67–e492.

2. Avila P, Mercier LA, Dore A et al. Adult congenital heart disease: A growing epidemic. Can J Cardiol 2014;30:S410–S419.

3. Simpson DL, Mishra R, Sharma S et al. A strong regenerative ability of cardiac stem cells derived from neonatal hearts. Circulation 2012;126:S46–S53.

4. Agarwal U, Smith AW, French KM et al. Age-dependent effect of pediatric cardiac progenitor cells after juvenile heart failure. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:883–892.

5. Tracy D, Maxwell JT, Brown ME et al. Aggregation of cell cardiac progenitor cells into spheres activates notch signaling and improves treatment of right ventricular heart failure. Circ Res 2019;124:526–538.

6. Agarwal U, George A, Bhutani S et al. Experimental, systems, and computational approaches to understanding the micromediated reparative potential of cardiac progenitor cell-derived exosomes from pediatric patients. Circ Res 2017;120:701–712.

7. Gray WD, French KM, Ghosh-Choudhary S et al. Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology. Circ Res 2015;116:255–263.

8. Park KY, Li WA, Platt MO. Patient-specific proteolytic activity of macrophage-derived macrophages and osteoclasts predicted with temporal kinase activation states during differentiation. Integr Biol 2012;4:1459–1469.

9. Platt MO, Wilder CL, Wells A et al. Multipathway kinase signatures of multipotent stromal cells are predictive for osteogenic differentiation: Tissue-specific stem cells. STEM CELLS 2009;27:2804–2814.

10. Hamada K, Sasaki T, Koni PA et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 2005;19:2054–2065.

11. Xue C, Xie J, Zhao D et al. The JAK/STAT3 signalling pathway regulates angiogenesis in an endothelial cell/adipose-derived stromal cell co-culture, 3D gel model. Cell Prolif 2017;50.

12. Rumjahn SM, Baldwin KA, Buxton IL. P2y receptor-mediated angiogenesis via vascular endothelial growth factor receptor 2 signaling. Proc West Pharmacol Soc 2007;50:58–60.

13. Walton CB, Ecker J, Anderson CD et al. Cardiac angiogenesis directed by stable hypoxia inducible factor-1. Vasc Cell 2011;2:1117–1133.

14. Ziche M, Morbidelli L. Nitric oxide and angiogenesis. J Neurooncol 2000;50:13–148.

15. Eyries M, Siegfried G, Ciumas M et al. Hypoxia-induced angiogenesis: Good and evil. Genes Cancer 2011;2:1117–1133.

16. Platt MO, Wilder CL, Wells A et al. Hypoxia-induced angiogenesis via vascular endothelial growth factor receptor 2 signaling. Proc West Pharmacol Soc 2007;50:58–60.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ACKNOWLEDGMENTS

We thank the Yerkes Genomics Core for miRNA sequencing and sequence alignment assistance. This work was supported by funds from Alliance Data, the Betkowski Family Fund, and HL145644 awarded to M.E.D., and by the American Heart Association Predoctoral Fellowship (17PRE33460129) awarded to D.T. The Yerkes NHP Genomics Core is supported in part by ORIP/OD P51OD011132.

AUTHOR CONTRIBUTIONS

D.T.: conception and design, financial support, administrative support, provision of study material or patients, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; J.R.H.: conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; S.B.: collection and/or assembly of data, data analysis and interpretation, final approval of manuscript; J.T.M.: conception and design, collection and/or assembly of data, data analysis and interpretation, final approval of manuscript; M.O.P.: data analysis and interpretation, manuscript writing, final approval of manuscript; M.E.D.: conception and design, financial support, administrative support, manuscript writing, final approval of manuscript.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicated no potential conflicts of interest.
17 Pchejetski D, Foussal C, Alfarano C et al. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J 2012;33:2360–2369.

18 Molkentin JD. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 2004;63:467–475.

19 Gude N, Joyo E, Toku H et al. Notch activation enhances lineage commitment and protective signaling in cardiac progenitor cells. Basic Res Cardiol 2015;110:1–15.

20 Boni A, Urbanek K, Nascimbene A et al. Notch1 regulates the fate of cardiac progenitor cells. Proc Natl Acad Sci USA 2008;105:15529–15534.

21 Boopathy AV, Martinez MD, Smith AW et al. Intramyocardial delivery of Notch ligand-containing hydrogels improves cardiac function and angiogenesis following infarction. Tissue Eng Part A 2015;21:2315–2322.

22 Li W, Lu Y, Han R et al. Gremlin2 regulates the differentiation and function of cardiac progenitor cells via the Notch signaling pathway. Cell Physiol Biochem 2018;47:579–589.

23 Kishore R, Khan M. More than tiny sacks: Stem cell exosomes as cell-free modality for cardiac repair. Circ Res 2016;118:330–343.

24 Han C, Sun X, Liu L et al. Exosomes and their therapeutic potentials of stem cells. Stem Cells Int 2016;2016:7653489.

25 Lang JK, Young RF, Ashraf H et al. Inhibiting extracellular vesicle release from human cardiophore derived cells with lentiviral knockdown of nSmase2 differentially effects proliferation and apoptosis in cardiomyocytes, fibroblasts and endothelial cells in vitro. PLoS One 2016;11:e0165926.

26 Ibrahim Ahmed G-E, Cheng K, Marbán E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Rep 2014;2:606–619.

27 Zhu X, Badawi M, Pomeroy S et al. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. J Extracell Vesicles 2017;6:1324730.

28 Willms E, Johansson H, Mäger I et al. Cells release subpopulations of exosomes with distinct molecular and biological properties. Sci Rep 2016;6:22519.

29 Arkesteijn GJA, van de Lest CHA, Stoovogel W et al. CD4+ T cell activation promotes the differential release of distinct populations of nanosized vesicles. J Extracell Vesicles 2012;1:18364.

30 Kojima R, Bojar D, Rizzi G et al. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment. Nat Commun 2018;9:1305.

31 Fischer KM, Cottage CT, Wu W et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation 2009;120:2077–2087.

32 Nowakowski A, Andrezewska A, Janowski M et al. Genetic engineering of stem cells for enhanced therapy. Acta Neurobiol Exp 2013;73:1–18.

33 Alsberg E, von Recum HA, Mahoney MJ. Environmental cues to guide stem cell fate decision for tissue engineering applications. Expert Opin Biol Ther 2006;6:847–866.

34 Choi S, Jung S, Asahara T et al. Direct comparison of distinct cardiomyogenic induction methodologies in human cardiac-derived c-kit positive progenitor cells. Tissue Eng Regen Med 2012;9:311–319.

35 Smith RR, Marbán E, Marbán L. Enhancing retention and efficacy of cardiophere-derived cells administered after myocardial infarction using a hyaluronan-gelatin hydrogel. Biomatter 2013;3:e24490.